• UK Study Demonstrates Real-World Value of Genetic Testing for Drug Prescribing

    Jun 26 | Bio-IT World | The UK's National Health Service is pioneering a new approach to precision medicine through pharmacogenomic testing that could transform how doctors prescribe medications and significantly reduce healthcare costs. Early results from the NHS PROGRESS trial suggest that genetic testing can guide prescribing decisions for nearly all patients, with one in four participants having their prescriptions adjusted for safer or more effective treatment. More

  • Follow the Money: ITM’s Gastroenteropancreatic Therapy, GRIN, Angelini Pharma Collaborates, More

    Jun 25 | Bio-IT World | ITM plans to use their financing to prepare for commercial readiness and potential market launch of the company’s lead candidate, n.c.a. 177Lu-edotreotide, which treats gastroenteropancreatic neuroendocrine tumors; GRIN and Angelini Pharma will develop and expand commercial rights outside of North America for GRIN's investigational drug radiprodil, which treats rare genetic epilepsies and neurodevelopmental disorders; and more. More

  • Pangaea Data, Alexion Collaboration, Dell to Develop Supercomputer, More

    Jun 24 | Bio-IT World | Pangaea Data has entered into a collaboration agreement with Alexion to develop an Artificial Intelligence Clinical Decision Support System; Dell Technologies will develop NERSC-10, the next flagship supercomputer at the National Energy Research Scientific Computing Center; and more. More

  • Nanoneedle Patch Enables Non-Invasive Tissue Sampling Offering Spatiotemporal Insights

    Jun 19 | Bio-IT World | Nanoneedle technology developed by researchers from King’s College London offers the ability to extract molecular information from living tissue without damaging or killing cells—offering spatial and longitudinal molecular insights that is described as a “fundamental scientific breakthrough.” More

  • Black Swan Initiative: Multi-Pronged Research Strategy Targets Multiple Myeloma Cure

    Jun 18 | Bio-IT World | The International Myeloma Foundation's ambitious Black Swan Research Initiative is orchestrating a global collaborative effort to achieve what has long eluded researchers: a true cure for multiple myeloma. Through research partnerships spanning five continents, the initiative is systematically testing multiple therapeutic approaches while revolutionizing how cancer drug approvals are evaluated. More

  • Pistoia Alliance’s FAIR Maturity Assessment Tool

    Jun 17 | Bio-IT World | Findable, Accessible, Interoperable and Reusable (FAIR) principles continue to hold an important place in data management and access, artificial intelligence (AI) and machine learning (ML) development, and data sharing between organizations. But FAIR is also complex to implement due to the original FAIR guidelines not being explicit and difficult to understand or visualize for non-experts. The FAIR community of experts with the Pistoia Alliance developed a self-assessment tool that can measure an organization’s FAIR maturity level. More

  • Veteran ‘Lord of the Flies’ Takes a Crack at Addiction

    Jun 12 | Bio-IT World | The brain of fruit flies and humans may be vastly different in size and complexity, but at the circuit level they are not all that different, according to a veteran fly geneticist who has spent much of his career trying to understand why humans abuse drugs. An interest in alcohol dependence segued to another major health problem, cocaine abuse disorder, which has some of the same genetic underpinnings. More

  • NVIDIA, Novo Nordisk Collaborate to Bring AI Agents to Drug Discovery

    Jun 11 | Bio-IT World | Today, NVIDIA announced a collaboration with Novo Nordisk to accelerate drug discovery efforts by creating customized AI models and agents that Novo Nordisk can use for early research and clinical development and to apply advanced simulation and physical AI technologies. More

  • A Farewell to Stan Gloss: Leading with Generosity and Other Words of Wisdom

    Jun 10 | Bio-IT World | BioTeam co-founder and host of Trends from the Trenches Stan Gloss is passing the torch to BioTeam CEO Ari Berman. Gloss founded BioTeam with William van Etten, Chris Dagdigian, and Michael Athanas 22 years ago and built an organization that focuses on helping scientists find solutions, manage data, and accelerate scientific innovation. In his last episode of Trends from the Trenches, Gloss is interviewed by Berman to discuss the founding of BioTeam and words of wisdom for those who are starting their own company. More

  • MIT Researchers Unveil Boltz-2: AI Model Predicts Protein Structure, Binding Affinity in Seconds

    Jun 06 | Bio-IT World | Researchers at MIT and Recursion today announced the release of Boltz-2, an updated artificial intelligence model that can predict protein structure (building on Boltz-1) and also binding affinity—how strongly potential drugs bind to their target proteins—in just 20 seconds with a single GPU. More
View more articles
Bio IT World Lead Gen

 
Industry-spotlight

Riffyn’s pioneering cloud system, Riffyn Nexus, delivers 2X faster development cycles and 4X productivity gains to the world’s most advanced scientific R&D organizations. Its process-centric experiment design, data capture, and data analytics overcome the limitations of ELN and LIMS systems. Its adaptive data integration engine delivers results that are always ready for machine learning.
Read more here!

Industry-spotlight
Trends from the Trenches

Bio-IT World’s Trends from the Trenches podcast delivers your insider’s look at the science, technology, and executive trends driving the life sciences through conversations with industry leaders. BioTeam co-founder Stan Gloss brings years of industry experience in science, data, and technology to conversations exploring what is driving data and discovery, and what’s coming next.
Listen today!